SRTCX1003 is a SIRT1 activator which suppresses inflammatory responses through promotion of p65 deacetylation and inhibition of NF-κB activity.
Uses
SRTCX1003 is an orally active SIRT1 activator. SRTCX1003 suppresses inflammatory responses[1].
in vivo
SRTCX1003 (3-100 mg/kg; oral; once) decreases LPS (HY-D1056)-stimulated TNFα and IL-12p40 production in mice inflammation model[1].
Animal Model:
Male BALB/c mice, LPS-induced inflammation mouse model[1]
Dosage:
3, 10, 30 and 100 mg/kg
Administration:
Oral, 60 minutes prior to LPS administration
Result:
Dose-dependently reduced LPS-stimulated TNFα and IL-12p40 production.
References
[1] Yang H, et al. SIRT1 activators suppress inflammatory responses through promotion of p65 deacetylation and inhibition of NF-κB activity. DOI:10.1371/journal.pone.0046364
